Company Overview of Mallinckrodt LLC
Mallinckrodt LLC manufactures and distributes products used in diagnostic procedures, and in the treatment of pain and related conditions. It offers addiction treatment products, and specialty generics and pharmaceuticals; and active pharmaceutical ingredients, including medicinal narcotics, acetaminophen/paracetamol, stearates, phosphates, and peptides, as well as analytical research samples for pharmaceutical companies and analytical laboratories. The company also supplies medical isotope technetium-99m; and radiopharmaceuticals, and contrast media and delivery systems. It serves customers in the United States and internationally. The company was founded in 1867 and is based in St. Louis, ...
675 McDonnell Boulevard
St. Louis, MO 63042
Founded in 1867
Key Executives for Mallinckrodt LLC
Mallinckrodt LLC does not have any Key Executives recorded.
Mallinckrodt LLC Key Developments
Mallinckrodt Pharmaceuticals Wins Award Solicitation for Pharmaceutical Ampules
Oct 30 14
Alabama Department of Finance, Division of Purchasing has posted its intent to award solicitation on October 29, 2014, to Mallinckrodt Pharmaceuticals for pharmaceutical ampules - drugs for $13,630 per lot.
Mallinckrodt Pharmaceuticals Launches OptiSync Data Management System in US
Sep 26 14
Mallinckrodt Pharmaceuticals has launched the OptiSync data management system as a new technology in its Global Medical Imaging segment, in US. The OptiSync system is designed to help healthcare professionals efficiently collect and analyze radiology data from when a patient undergoes a contrast media-enhanced computed tomography (CT) diagnostic imaging procedure. The OptiSync system is used with the OptiVantage dual-head CT contrast delivery system, and allows users to verify and log patient and pharmaceutical information with the scan of a barcode. As injection data is collected, the OptiSync system transmits patient, drug, dose and administration information to HL7-based healthcare systems and automates patient record updates. By assembling a database that includes contrast media usage, spend, workflow and benchmarking across all users, scanners and facilities, the OptiSync system can help users identify areas where they can reduce errors, increase productivity or improve efficiency.
Nuvo Research Inc. Enters into Settlement Agreement with Mallinckrodt Inc
Sep 11 14
Nuvo Research Inc. has entered into a settlement agreement with Mallinckrodt Inc. for a litigation relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid and Pennsaid 2% in the US. Under the terms of the settlement agreement, Mallinckrodt will return all US rights to Pennsaid and Pennsaid 2% to Nuvo after a brief transition period and pay USD 10 million. Pennsaid is used to treat the signs and symptoms associated with knee osteoarthritis (OA). The drug combines the transdermal carrier (containing dimethyl sulfoxide, popularly known as DMSO) with 1.5% diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID) and delivers the active drug through the skin directly to the site of inflammation and pain. Pennsaid is currently marketed in the US by Mallinckrodt, in Canada by Paladin Labs Inc. and marketed under license and/or distribution agreements in Greece, Italy and the UK.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|